Novartis to file for two new potential blockbusters, restates Chiron interest

Share this article:
Novartis plans to submit two potential blockbuster drugs for U.S. regulatory approval in early 2006, the drugmaker said prior to its pipeline update in London today.
Novartis' plans include filing for FDA approval for an experimental diabetes drug vildagliptin, also known as LAF237, and another drug, the first in a new class of blood pressure-lowering medications, called Aliskiren or SPP100.
Vildagliptin belongs to a new class of drugs called dipeptidyl-peptidase IV, or DPP-IV inhibitors and possesses blockbuster potential, said Joerg Reinhardt, head of development at Novartis, during a conference call with reporters. Merck is also developing a drug in this class called sitagliptin.
The blood pressure drug Aliskiren was developed in combination with Speedel, a Swiss biopharmaceutical company.
Novartis was expected to present two studies on Aliskiren at its pipeline update today.
Reinhardt told reporters he also expects Aliskiren to achieve blockbuster status.
Meanwhile, Novartis chief executive Daniel Vasella reiterated the company's willingness to control U.S. vaccine company Chiron.
"Chiron faces a multitude of challenges it can better address as a Novartis entity," Vasella said at a presentation to analysts in London, a Wall Street Journal article today reported.
A Novartis spokesman told the newspaper that the company has no intention of overpaying and has a walk-away price.
Novartis currently has a 42-percent stake in Chiron. Last month, Novartis decided to take control of Chiron, offering to pay $4.5 billion for the remaining 58 percent it doesn't own. Chiron rejected the bid as too low.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...